Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205343 · ClinicalTrials.gov registry record
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
A clinical trial of GastroEsophageal Cancer and Gastrostomy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 20
- Enrollment target
- 4
- Study locations
NCT05205343 is a study of GastroEsophageal Cancer and Gastrostomy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05205343, a study of GastroEsophageal Cancer and Gastrostomy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER Control Group
Study Locations (4)
Other
- Keio University School of Medicine - Tokyo
- Yonsei University College of Medicine - Soeul
Minnesota
- Mayo Clinic in Rochester - Rochester
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05205343
The ClinicalTrials.gov registry entry for NCT05205343 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT05205343 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT05205343 about?
NCT05205343 is a clinical study titled "Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers". To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
What is the current status of trial NCT05205343?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-05-11. Estimated completion is 2026-05-31.
What conditions does trial NCT05205343 study?
This clinical trial studies the following conditions: GastroEsophageal Cancer, Gastrostomy, Gastric.
What interventions are being tested in trial NCT05205343?
The interventions under investigation include: Standard of Care (OTHER), Control Group (OTHER).
Who is sponsoring clinical trial NCT05205343?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05205343 being conducted?
This trial has 4 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroEsophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
RECRUITING · NA
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
RECRUITING · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.